Correlation Between Agenus and Icosavax
Can any of the company-specific risk be diversified away by investing in both Agenus and Icosavax at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Agenus and Icosavax into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Agenus Inc and Icosavax, you can compare the effects of market volatilities on Agenus and Icosavax and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Agenus with a short position of Icosavax. Check out your portfolio center. Please also check ongoing floating volatility patterns of Agenus and Icosavax.
Diversification Opportunities for Agenus and Icosavax
Excellent diversification
The 3 months correlation between Agenus and Icosavax is -0.55. Overlapping area represents the amount of risk that can be diversified away by holding Agenus Inc and Icosavax in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Icosavax and Agenus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Agenus Inc are associated (or correlated) with Icosavax. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Icosavax has no effect on the direction of Agenus i.e., Agenus and Icosavax go up and down completely randomly.
Pair Corralation between Agenus and Icosavax
If you would invest 902.00 in Icosavax on August 30, 2024 and sell it today you would earn a total of 0.00 from holding Icosavax or generate 0.0% return on investment over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 1.56% |
Values | Daily Returns |
Agenus Inc vs. Icosavax
Performance |
Timeline |
Agenus Inc |
Icosavax |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Agenus and Icosavax Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Agenus and Icosavax
The main advantage of trading using opposite Agenus and Icosavax positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Agenus position performs unexpectedly, Icosavax can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Icosavax will offset losses from the drop in Icosavax's long position.Agenus vs. Marker Therapeutics | Agenus vs. Edgewise Therapeutics | Agenus vs. Adaptimmune Therapeutics Plc | Agenus vs. Mereo BioPharma Group |
Icosavax vs. Terns Pharmaceuticals | Icosavax vs. Amylyx Pharmaceuticals | Icosavax vs. Acumen Pharmaceuticals | Icosavax vs. Inozyme Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Complementary Tools
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |